The patent covers a specially designed transdermal or transmucosal formulation to treat hypoactive sexual desire disorder (HSDD) or female sexual dysfunction (FSD).
The method may also be used to treat surgically menopausal and naturally menopausal females, as well as pre-menopausal females with low testosterone levels.
Antares Pharma president and CEO Paul Wotton said as their partner, BioSante, continues to make substantial development progress for LibiGel, they are pleased to announce the issuance of this important patent, providing additional intellectual property protection for the use of the product.